UBS analyst AJ Rice lowered the firm’s price target on Acadia Healthcare (ACHC) to $28 from $31 and keeps a Buy rating on the shares. Payer issues and Medicaid volume softness are likely to continue, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare Reports Q3 Revenue Growth Amid Challenges
- Acadia Healthcare sentiment likely to worsen further, says Cantor Fitzgerald
- Acadia Healthcare COO Nasser Khan resigns
- Acadia Healthcare lowers FY25 adjusted EPS $2.35-$2.45 from $2.45-$2.65
- Acadia Healthcare taking ‘decisive action to drive improved performance’